1 May 2025 in Current Cancer Therapy Reviews
Cancer remains a formidable global health challenge, necessitating innovative therapeutic strategies. Traditional small-molecule inhibitors often face limitations in selectively targeting disease associated proteins, leading to side effects and incomplete therapeutic responses. Proteolysis targeting chimeras (PROTACs) have emerged as a promising approach to address these challenges. Unlike traditional inhibitors, PROTACs leverage the cellular ubiquitin-proteasome system to selectively degrade disease-associated proteins. In this review, we discuss PROTACs as a targeted approach for cancer management, highlighting key findings, limitations, and future perspectives. For this, the authors have critically reviewed literature obtained from prime sources comprising Google Scholar, Web of Science, PubMed, and Publons. Additional relevant articles were retrieved from the reference sections of selected papers. Preclinical studies and early-phase clinical trials have demonstrated the efficacy and potential of PROTACs in cancer management. Additionally, the potential of PROTACs in overcoming therapy resistance, tackling tumor heterogeneity, and engaging multiple pathways is explored. As research advances, addressing challenges and refining PROTAC technology will pave the way for their integration into the next generation of cancer therapeutics, marking a transformative era in precision medicine.
30 September 2023 in Biomedical and Pharmacology Journal
The current study proposed the “Nanoparticles -A Booming Drug Delivery System in Chemotherapy” is a Novel targeted approach which enhances the efficacy of chemotherapeutic agents by reducing the dose-related side effect as well as mortality rate a in patients due to its non-immunogenic, nontoxic nature. Drug bioavailability, drug solubility, drug biodistribution, drug resistance brought on by treatment, and nonspecific toxicity can all be improved with the development of nanoparticle chemotherapeutic drug delivery applications based on nanotechnology. It possesses active as well as passive targeting of tumour cells. Due to this reason, a wide range of chemotherapeutic agents like cisplatin, taxol, doxorubicin, and carboplatin are extensively utilized for treating cancer. Deep tissue penetration of nanoparticles is found to increase the enhanced permeability and retention (EPR) effect. There are some limitations with conventional drug delivery system which is minimized by utilizing nanoparticles as a drug delivery system. The current review has focused on targeted strategies and novel approaches in cancer treatment with nanoparticles.
25 May 2025 in Discover Artificial Intelligence
Background Artificial intelligence (AI) has become a novel approach for bioactive molecule search, target identification, prediction of lead molecule-target interaction, design of pharmaceutical formulations, and efficient conduction and prediction of results of clinical trials. Main body AI has revolutionized the drug discovery and pharmaceutical product development. Traditional methods are time-consuming and costlier due to large experimentation number and low hit and success. Herein, AI can analyse a large dataset quickly to give possible outcomes. AI easily identifies potential drug targets by virtual screening of biological data, resulting in time-efficient and low-cost discovery of novel drug targets. AI can be used for the design of new drug candidates by analysing the possible molecular structures binding with targets. Moreover, AI can easily predict drug interactions with targets to exert therapeutic action. AI-enabled drug repurposing is based on the interaction of existing drugs with new targets or other explored target datasets. AI can play prominent role in accelerating the development of pharmaceutical products due to their role in optimization and process validation. The clinical trials have also become easy and faster with use of AI tools. Conclusion Artificial Intelligence based tool can be employed in discovery of lead molecule, target identification, drug-target interaction, development of pharmaceutical product and clinical trials to accelerate the production of clinically acceptable therapeutics with higher success rate.